ArticleThe Annals of thoracic surgery2020
Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (≤2 cm) Non-Small Cell Lung Cancer.
Article in The Annals of thoracic surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Routine intraoperative frozen section assessment of lymph nodes in clinical stage IA non-small cell lung cancer: towards a risk-stratified approach.Journal of thoracic disease · 2026Article
- The cost of knowing: should frozen section pathology be used routinely for the assessment of lymph nodes in clinical stage IA non-small cell lung cancer?Journal of thoracic disease · 2026Article
- Outcome of segmentectomy vs. lobectomy in patients with cT1a-b N0 lung cancer and postoperative N1 upstaging.Langenbeck's archives of surgery · 2026Article
- Prognostic factors in resected non-small cell lung cancer with pathological N1 lymph node involvement: a survival analysis.Journal of cardiothoracic surgery · 2026Article
- GCC2 in Small Extracellular Vesicles as a Diagnostic and Prognostic Biomarker of Early-Stage Lung Adenocarcinoma.Journal of extracellular vesicles · 2026Article
- Balancing oncological control and immune preservation in the immunotherapy era: revisiting lymph node dissection in non-small cell lung cancer.Frontiers in oncology · 2025Review
- Standardized intrapulmonary lymph node dissection in lung cancer specimens: A national Colombian analysis.JTCVS open · 2024Article
- Predicting lymph node metastasis of clinical T1 non-small cell lung cancer: a brief review of possible methodologies and controversies.Frontiers in oncology · 2024Review
- Is tumor diameter a risk factor for occult N1 metastasis in patients with peripheral non-small cell lung cancer which is smaller than 3 cm?Updates in surgery · 2023Article
- Nomograms for intraoperative prediction of lymph node metastasis in clinical stage IA lung adenocarcinoma.Cancer medicine · 2023Article
- Analysis of prognostic factors in pT1-2 N1 lung cancer patients in the light surgical results.Updates in surgery · 2023Article
- Characterization of TIM-3 Expression and Its Correlation with TNF-Disease markers · 2023Article
- Review
- Prognostic implication of isolated pulmonary nodules in patients with a history of breast cancer.Journal of cardiothoracic surgery · 2022Article
- Review
- Lymph node metastases outside tumor-bearing lobes and/or segments in non-small cell lung cancer.Frontiers in medicine · 2022Article
- Preoperative consolidation-to-tumor ratio is effective in the prediction of lymph node metastasis in patients with pulmonary ground-glass component nodules.Thoracic cancer · 2021Article
- Stereotactic body radiation therapy (SBRT) for patients with stage I non-small cell lung cancer is applicable to more tumors than sublobar resection.Journal of thoracic disease · 2021Article
- Surgical treatment of small-sized non-small cell lung cancer-a dilemma for surgeons.Journal of thoracic disease · 2020Article
- An Externally-Validated Dynamic Nomogram Based on Clinicopathological Characteristics for Evaluating the Risk of Lymph Node Metastasis in Small-Size Non-small Cell Lung Cancer.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThere has been growing interest in limited resection and nonsurgical treatment for small lung cancers. We examined the pattern and rate of occult N1 nodal metastasis in patients with peripheral, small (≤2 cm), clinically node-negative non-small cell lung cancer (NSCLC).
methodsPatients with peripheral small (≤2 cm) NSCLC with no evidence of locally advanced or metastatic disease (clinical T1a-b N0 M0, American Joint Committee on Cancer 8th Edition Cancer Staging Manual), who were deemed eligible for lobectomy or sublobar resection, were identified from preregistration eligibility screening logs for the Alliance/Cancer and Leukemia Group B 140503 trial at our institution. Pathologic outcomes were examined in all patients undergoing anatomic resection with mediastinal and hilar lymphadenectomy.
resultsIncluded were 58 patients treated between November 2014 and January 2017 who met the inclusion criteria: 51 underwent lobectomy, and 7 underwent segmentectomy. Mean tumor diameter on computed tomography was 1.5 cm, and mean positron emission tomography maximal standardized uptake value was 3.9. The mean consolidation-to-tumor ratio was 0.77. Occult nodal metastases in N1 stations were found in 8 of 58 patients (14%), and most of these nodes were found in interlobar or peribronchial stations (11 or 12). An additional 2 patients (3%) had occult positive N2 nodes. Overall, the false-negative rate for clinical staging was 16%.
conclusionsOccult nodal disease was frequently identified in peripheral N1 stations (11-13) in patients with small (≤2 cm) clinical N0 NSCLC. Hilar lymphadenectomy is essential for accurate staging in the management of patients with small clinical N0 NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.